Acad stock zacks
Stocks Rankings for ACAD. U.S. News compares companies to their industry peers based on a variety of company fundamentals, performance metrics and investor preferences to help you find the right Shares of Seanergy Maritime Holdings Corp. (NASDAQ:SHIP) have received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation. Brokers have set a 12-month consensus price objective of $1.30 for the company and […] ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates. ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact. Stock declines in after-hours trading. ACAD: Changes To Phase 3 -020 Study Should Bring Positive Results Small-Cap Research scr.zacks.com 111 North Canal Street, Chicago, IL 60606 January 13, 2012 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com ZACKS ESTIMATES Revenue (In millions of $) Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec) 2010 2.1 A 2.3 A 2.3 A 35.4 A 42.1 A
We expect an in-line return from the stock in the next few months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here.
Real time Acadia Pharmaceuticals (ACAD) stock price quote, stock graph, news & analysis. Wed, May 27, 10:15 AM, Zacks ACADIA to Merge Two Phase III Studies on Nuplazid for MDD ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3. Fri, May 8, 8:55 AM, Zacks ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. For the ACAD price target at the top of this page, we present the average ACAD target price across the 14 analysts covering ACAD, as reported in data provided by Zacks Investment Research via Quandl.com.The median ACAD price target (a different metric than the
ACAD Stock Price, Forecast & News (ACADIA Pharmaceuticals)
ACAD: ACADIA Pharmaceuticals Inc broker recommendations. Get the latest broker recommendations from Zacks Investment Research. ACAD: ACADIA Pharmaceuticals Inc - Earnings Announcements. Stay up to date with lastest Earnings Announcements for ACADIA Pharmaceuticals Inc from Zacks Investment Research Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results. ACAD: ACADIA Pharmaceuticals Inc broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research. Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results. ACAD: ACADIA Pharmaceuticals Inc Detailed Estimate. Get the latest Detailed Estimate from Zacks Investment Research. Zacks' proprietary data indicates that ACADIA Pharmaceuticals Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the ACAD shares relative to the market in the
ACAD News Today (ACADIA Pharmaceuticals) | MarketBeat
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates May 08, 2020
Positive Developments for These 3 Biotech Stocks We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics.
Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. ACADIA Pharmaceuticals Inc. ACAD reported fourth-quarter 2019 loss of 34 cents per share, narrower than the Zacks Consensus Estimate of a loss of 37 cents as well as the year-ago loss of 50 cents. Total revenues comprising net sales of the sole marketed drug Nuplazid (pimavanserin) soared 65% year over year to $98.3 million in the fourth quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ACADIA Pharmaceuticals Inc (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research